At the ACTRIMS Forum 2021, February 25-27, Janssen Pharmaceutical presented 2 abstracts that focused on the impact of fatigue symptoms in patients with relapsing multiple sclerosis (RMS). The first of the 2 measured the symptoms using the RMS-specific Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) in a real-world population study that included 300 patients with RMS.1,2
The second study evaluated the impact these symptoms have on work productivity and activity impairment using longitudinal data from the phase 3 OPTIMUM study (NCT02425644). Both studies highlighted the burden that fatigue has among patients with MS and how it can influence a patient’s daily functioning and life. Additionally, they both echo the need to construct disease-modifying therapies (DMTs) to treat this symptom, an area that currently has no specific treatment options available.
For more coverage of ACTRIMS 2021, click here.